Annual report
4587.TEDINET S100RF5D
Period2022-01-01 → 2022-12-31
Filed2023-07-18
StandardIFRS
ConsolidatedYes
Data checks20 of 24 passed
Amends S100QIHD. Amended by S100RF5K (2023-07-18).
Key figures · 153
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥26.9bn | 2022-01-01 → 2022-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥9.4bn | 2021-01-01 → 2021-12-31 | Cons. | Revenue IFRS |
| Operating income | ¥9.0bn | 2022-01-01 → 2022-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥4.1bn | 2021-01-01 → 2021-12-31 | Cons. | Operating profit loss IFRS |
| Ordinary income | ¥8.1bn | 2022-01-01 → 2022-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥6.7bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥3.8bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥7.6bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥6.6bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.6bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥7.6bn | 2022-01-01 → 2022-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥2.6bn | 2021-01-01 → 2021-12-31 | Cons. | Profit loss IFRS |
| Total assets | ¥63.9bn | at 2022-12-31 | Cons. | Assets IFRS |
| Total assets | ¥60.1bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total assets | ¥27.0bn | at 2021-12-31 | Cons. | Assets IFRS |
| Total assets | ¥26.1bn | at 2020-12-31d | Cons. | Assets IFRS |
| Total liabilities | ¥31.8bn | at 2022-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥1.7bn | at 2021-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥4.9bn | at 2020-12-31d | Cons. | Liabilities IFRS |
| Net assets / equity | ¥32.0bn | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥30.5bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥25.4bn | at 2021-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥21.3bn | at 2020-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥32.0bn | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥25.4bn | at 2021-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥21.3bn | at 2020-12-31d | Cons. | Equity attributable to owners of parent IFRS |
| Cash & equivalents | ¥5.2bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥11.7bn | at 2021-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥7.1bn | at 2020-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | −¥83m | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥350m | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥6.7bn | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥27.4bn | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥27.3bn | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.3bn | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥20.8bn | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥21.0bn | 2022-01-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥66m | 2021-01-01 → 2021-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥58.19 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥51.13 | 2022-01-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥19.96 | 2021-01-01 → 2021-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥58.14 | 2022-01-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥19.81 | 2021-01-01 → 2021-12-31 | Cons. | Diluted earnings loss per share IFRS |
| Net assets per share | ¥234.8 | at 2022-12-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥246.63 | at 2022-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥195.1 | at 2021-12-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥168.1 | at 2020-12-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 50.5% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.2% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 93.8% | at 2021-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 81.4% | at 2020-12-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 24.4% | 2022-01-01 → 2022-12-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 26.3% | 2022-01-01 → 2022-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 11.0% | 2021-01-01 → 2021-12-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 569 | at 2022-12-31 | Cons. | Number of employees |
| Employees | 141 | at 2021-12-31 | Cons. | Number of employees |
| Employees | 128 | at 2020-12-31d | Cons. | Number of employees |
| Revenue | ¥15.4bn | 2022-01-01 → 2022-12-31 | Standalone | Net sales |
| Revenue | ¥9.4bn | 2021-01-01 → 2021-12-31 | Standalone | Net sales |
| Revenue | ¥11.7bn | 2020-01-01 → 2020-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.0bn | 2019-01-01 → 2019-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥7.2bn | 2018-01-01 → 2018-12-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥6.4bn | 2017-01-01 → 2017-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥9.1bn | 2022-01-01 → 2022-12-31 | Standalone | Operating income |
| Operating income | ¥4.4bn | 2021-01-01 → 2021-12-31 | Standalone | Operating income |
| Ordinary income | ¥8.8bn | 2022-01-01 → 2022-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥4.8bn | 2021-01-01 → 2021-12-31 | Standalone | Ordinary income |
| Ordinary income | ¥7.0bn | 2020-01-01 → 2020-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥707m | 2019-01-01 → 2019-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.8bn | 2018-01-01 → 2018-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.2bn | 2017-01-01 → 2017-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥6.9bn | 2022-01-01 → 2022-12-31 | Standalone | Income before income taxes |
| Profit before tax | ¥4.8bn | 2021-01-01 → 2021-12-31 | Standalone | Income before income taxes |
| Net income | ¥4.3bn | 2022-01-01 → 2022-12-31 | Standalone | Profit loss |
| Net income | ¥3.6bn | 2021-01-01 → 2021-12-31 | Standalone | Profit loss |
| Net income | ¥4.4bn | 2020-01-01 → 2020-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥488m | 2019-01-01 → 2019-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥2.8bn | 2018-01-01 → 2018-12-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥2.3bn | 2017-01-01 → 2017-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥55.2bn | at 2022-12-31 | Standalone | Assets |
| Total assets | ¥26.6bn | at 2021-12-31 | Standalone | Assets |
| Total assets | ¥26.3bn | at 2020-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥17.8bn | at 2019-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥20.0bn | at 2018-12-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥16.5bn | at 2017-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥25.8bn | at 2022-12-31 | Standalone | Liabilities |
| Total liabilities | ¥1.6bn | at 2021-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥29.4bn | at 2022-12-31 | Standalone | Net assets |
| Net assets / equity | ¥25.0bn | at 2021-12-31 | Standalone | Net assets |
| Net assets / equity | ¥21.2bn | at 2020-12-31d | Standalone | Net assets |
| Net assets / equity | ¥17.0bn | at 2019-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥17.4bn | at 2018-12-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥14.7bn | at 2017-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥847m | at 2022-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥11.7bn | at 2021-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥11.7bn | at 2021-12-31 | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥7.1bn | at 2020-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥7.0bn | at 2019-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥6.9bn | at 2018-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥3.5bn | at 2017-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥6.7bn | 2021-01-01 → 2021-12-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.7bn | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥242m | 2019-01-01 → 2019-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥4.5bn | 2018-01-01 → 2018-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.0bn | 2017-01-01 → 2017-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.3bn | 2021-01-01 → 2021-12-31 | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.2bn | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥138m | 2019-01-01 → 2019-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.3bn | 2018-01-01 → 2018-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥4.2bn | 2017-01-01 → 2017-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥66m | 2021-01-01 → 2021-12-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥237m | 2020-01-01 → 2020-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥29m | 2018-01-01 → 2018-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥170m | 2017-01-01 → 2017-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥33.11 | 2022-01-01 → 2022-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.98 | 2021-01-01 → 2021-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.4 | 2020-01-01 → 2020-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.9 | 2019-01-01 → 2019-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥22.42 | 2018-01-01 → 2018-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥19.35 | 2017-01-01 → 2017-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥27.78 | 2021-01-01 → 2021-12-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥34.26 | 2020-01-01 → 2020-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥21.33 | 2018-01-01 → 2018-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥17.79 | 2017-01-01 → 2017-12-31d | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥226.48 | at 2022-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥192.39 | at 2021-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥168.1 | at 2020-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥134.97 | at 2019-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥138.73 | at 2018-12-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥119.31 | at 2017-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 53.2% | at 2022-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.8% | at 2021-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.5% | at 2020-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 94.8% | at 2019-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 86.6% | at 2018-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.6% | at 2017-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 15.8% | 2022-01-01 → 2022-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.6% | 2021-01-01 → 2021-12-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 23.4% | 2020-01-01 → 2020-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.3% | 2018-01-01 → 2018-12-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 17.4% | 2017-01-01 → 2017-12-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 130,010,400 | at 2022-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 130,010,400 | at 2021-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 125,910,400 | at 2020-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 125,310,400 | at 2019-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 125,310,400 | at 2018-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 122,714,400 | at 2017-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 155 | at 2022-12-31 | Standalone | Number of employees |
| Employees | 141 | at 2021-12-31 | Standalone | Number of employees |
| Employees | 128 | at 2020-12-31d | Standalone | Number of employees |
| Employees | 107 | at 2019-12-31d | Standalone | Number of employees |
| Employees | 104 | at 2018-12-31d | Standalone | Number of employees |
| Employees | 83 | at 2017-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 15
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-01-01 → 2022-12-31 | −¥27m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-01-01 → 2022-12-31 | −¥27m |
| Drug Discovery And Development Businessreportable segment | employees | at 2022-12-31 | 155 pure |
| Drug Discovery And Development Businessreportable segment | revenue | 2022-01-01 → 2022-12-31 | ¥15.4bn |
| Drug Discovery And Development Businessreportable segment | revenue external | 2022-01-01 → 2022-12-31 | ¥15.4bn |
| Drug Discovery And Development Businessreportable segment | segment profit | 2022-01-01 → 2022-12-31 | ¥9.2bn |
| Radiopharmaceuticals Businessreportable segment | employees | at 2022-12-31 | 414 pure |
| Radiopharmaceuticals Businessreportable segment | revenue | 2022-01-01 → 2022-12-31 | ¥11.5bn |
| Radiopharmaceuticals Businessreportable segment | revenue external | 2022-01-01 → 2022-12-31 | ¥11.4bn |
| Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2022-01-01 → 2022-12-31 | ¥27m |
| Radiopharmaceuticals Businessreportable segment | segment profit | 2022-01-01 → 2022-12-31 | ¥236m |
| —segment total | revenue | 2022-01-01 → 2022-12-31 | ¥26.9bn |
| —segment total | revenue external | 2022-01-01 → 2022-12-31 | ¥26.9bn |
| —segment total | revenue intersegment | 2022-01-01 → 2022-12-31 | ¥27m |
| —segment total | segment profit | 2022-01-01 → 2022-12-31 | ¥9.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,501
| Item | Context | Value | Unit |
|---|---|---|---|
| Share of loss profit of investments accounted for using equity method ope cf IFRS | CurrentYearDuration | 203275000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | Prior1YearDuration | 6583442000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | CurrentYearDuration | -11286614000 | JPY |
| Decrease increase in inventories ope cf IFRS | Prior1YearDuration | -339157000 | JPY |
| Decrease increase in inventories ope cf IFRS | CurrentYearDuration | -656492000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | Prior1YearDuration | -1621162000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | CurrentYearDuration | 1453713000 | JPY |
| Increase or decrease in retirement benefit asset or liability ope cf IFRS | Prior1YearDuration | － | JPY |
| Increase or decrease in retirement benefit asset or liability ope cf IFRS | CurrentYearDuration | 103859000 | JPY |
| Other changes in working capital ope cf IFRS | Prior1YearDuration | -433749000 | JPY |
| Other changes in working capital ope cf IFRS | CurrentYearDuration | 1992444000 | JPY |
| Subtotal ope cf IFRS | Prior1YearDuration | 9038397000 | JPY |
| Subtotal ope cf IFRS | CurrentYearDuration | 453813000 | JPY |
| Interest and dividends received ope cf IFRS | Prior1YearDuration | 283000 | JPY |
| Interest and dividends received ope cf IFRS | CurrentYearDuration | 1334000 | JPY |
| Interest paid ope cf IFRS | Prior1YearDuration | － | JPY |
| Interest paid ope cf IFRS | CurrentYearDuration | -148837000 | JPY |
| Income taxes paid ope cf IFRS | Prior1YearDuration | -2384104000 | JPY |
| Income taxes paid ope cf IFRS | CurrentYearDuration | -441013000 | JPY |
| Income taxes refund ope cf IFRS | Prior1YearDuration | 131000 | JPY |
| Income taxes refund ope cf IFRS | CurrentYearDuration | 51772000 | JPY |
| Net cash provided by used in operating activities IFRS | Prior1YearDuration | 6654708000 | JPY |
| Net cash provided by used in operating activities IFRS | CurrentYearDuration | -82929000 | JPY |
| Proceeds from sale of marketable securities inv cf IFRS | Prior1YearDuration | 145222000 | JPY |
| Proceeds from sale of marketable securities inv cf IFRS | CurrentYearDuration | － | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | Prior1YearDuration | － | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | CurrentYearDuration | -23460335000 | JPY |
| Acquisition of shares of subsidiaries and affiliates inv cf IFRS | Prior1YearDuration | -943265000 | JPY |
| Acquisition of shares of subsidiaries and affiliates inv cf IFRS | CurrentYearDuration | － | JPY |
| Loan advances to subsidiaries and associates inv cf IFRS | Prior1YearDuration | -414097000 | JPY |
| Loan advances to subsidiaries and associates inv cf IFRS | CurrentYearDuration | － | JPY |
| Collection of loans receivable inv cf IFRS | Prior1YearDuration | 6241000 | JPY |
| Collection of loans receivable inv cf IFRS | CurrentYearDuration | 69047000 | JPY |
| Grant amount received inv cf IFRS | Prior1YearDuration | 137071000 | JPY |
| Grant amount received inv cf IFRS | CurrentYearDuration | － | JPY |
| Purchase of property plant and equipment inv cf IFRS | Prior1YearDuration | -1185973000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | CurrentYearDuration | -3720595000 | JPY |
| Purchase of intangible assets inv cf IFRS | Prior1YearDuration | -28705000 | JPY |
| Purchase of intangible assets inv cf IFRS | CurrentYearDuration | -254821000 | JPY |
| Other inv cf IFRS | Prior1YearDuration | 55000 | JPY |
| Other inv cf IFRS | CurrentYearDuration | -10511000 | JPY |
| Net cash provided by used in investing activities IFRS | Prior1YearDuration | -2283450000 | JPY |
| Net cash provided by used in investing activities IFRS | CurrentYearDuration | -27377217000 | JPY |
| Net increase decrease in short term borrowings fin cf IFRS | Prior1YearDuration | － | JPY |
| Net increase decrease in short term borrowings fin cf IFRS | CurrentYearDuration | 500000000 | JPY |
| Proceeds from long term borrowings fin cf IFRS | Prior1YearDuration | － | JPY |
| Proceeds from long term borrowings fin cf IFRS | CurrentYearDuration | 22400000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1YearDuration | － | JPY |
| Repayments of long term borrowings fin cf IFRS | CurrentYearDuration | -1680000000 | JPY |
| Payments of borrowing fee fin cf IFRS | Prior1YearDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 20 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | mismatch |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | mismatch |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | mismatch |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | mismatch |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |